{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:09:34Z","timestamp":1792112974740,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.phrs.2024.107312","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T20:28:55Z","timestamp":1721334535000},"page":"107312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["IUPHAR review \u2013\u00a0Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target"],"prefix":"10.1016","volume":"207","author":[{"given":"Nicolaus","family":"Bruns VI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Tressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro F.","family":"Vendruscolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HRP.0000000000000271","article-title":"Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments","volume":"28","author":"Connery","year":"2020","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.15585\/mmwr.mm7015a1","article-title":"C. state-level economic costs of opioid use disorder and fatal opioid overdose \u2014 united states, 2017","volume":"70","author":"Luo","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/09637214211026984","article-title":"The profound heterogeneity of substance use disorders: Implications for treatment development","volume":"30","author":"Carroll","year":"2021","journal-title":"Curr. Dir. Psychol. Sci."},{"key":"10.1016\/j.phrs.2024.107312_bib4","unstructured":"SAMHSA. (2024). Medications for Substance use Disorders. Substance Abuse and Mental Health Services Administration. Retrieved June 10 from \u3008https:\/\/www.samhsa.gov\/medications-substance-use-disorders\u3009."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2024.107312_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2024.107312_bib7","series-title":"What are Treatments for Tobacco dependence","author":"NIDA","year":"2021"},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"issue":"14","key":"10.1016\/j.phrs.2024.107312_bib9","doi-asserted-by":"crossref","first-page":"1063033","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"2023","author":"Jerlhag","year":"2023","journal-title":"Front. Pharm."},{"issue":"19","key":"10.1016\/j.phrs.2024.107312_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2024.107312_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the glucagonlike peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization","volume":"159","author":"Jensen","year":"2017","journal-title":"Endocrinology"},{"issue":"14","key":"10.1016\/j.phrs.2024.107312_bib16","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/cne.24905","article-title":"A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain","volume":"528","author":"Graham","year":"2020","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.phrs.2024.107312_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci."},{"issue":"11","key":"10.1016\/j.phrs.2024.107312_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113304","article-title":"Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab."},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2024.107312_bib21","series-title":"The Laboratory Rat (Third Edition)","first-page":"967","article-title":"Chapter 26 - Rat Models of Alcohol Use Disorder","author":"Tunstall","year":"2020"},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib23","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats","volume":"10","author":"Vall\u00f6f","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","article-title":"Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem Res."},{"key":"10.1016\/j.phrs.2024.107312_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","author":"Fink-Jensen","year":"2024","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107312_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front. Neurosci."},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib30","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1476-5381.2011.01754.x","article-title":"Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways","volume":"165","author":"Lan","year":"2012","journal-title":"Br. J. Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2024.107312_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2024.107312_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180512","article-title":"Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats","volume":"14","author":"Aran\u00e4s","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.phrs.2024.107312_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2024.107312_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.582147","article-title":"Drug-induced conditioned place preference and its practical use in substance use disorder research","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front. Behav. Neurosci."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061965","article-title":"Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward","volume":"8","author":"Shirazi","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2024.107312_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.alcohol.2013.08.006","article-title":"Operant alcohol self-administration in dependent rats: focus on the vapor model","volume":"48","author":"Vendruscolo","year":"2014","journal-title":"Alcohol"},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","article-title":"Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL\/6J mice","volume":"240","author":"D\u00edaz-Megido","year":"2023","journal-title":"Psychopharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib39","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice","volume":"40","author":"S\u00f8rensen","year":"2016","journal-title":"Alcohol Clin. Exp. Res"},{"key":"10.1016\/j.phrs.2024.107312_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents","volume":"103","author":"Vall\u00f6f","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2024.107312_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents","volume":"149","author":"Vall\u00f6f","year":"2019","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2024.107312_bib42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1037\/pha0000620","article-title":"Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice","volume":"31","author":"Allingbjerg","year":"2023","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107312_bib43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/WNR.0000000000001071","article-title":"Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats","volume":"29","author":"Abtahi","year":"2018","journal-title":"Neuroreport"},{"issue":"24","key":"10.1016\/j.phrs.2024.107312_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249710","article-title":"Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food","volume":"21","author":"Colvin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107312_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113726","article-title":"Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats","volume":"421","author":"Colvin","year":"2022","journal-title":"Behav. Brain Res."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib46","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/acer.14437","article-title":"Glucagon-like peptide-1 receptor signaling in the ventral tegmental area reduces alcohol self-administration in male rats","volume":"44","author":"Dixon","year":"2020","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib47","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1530\/EC-19-0317","article-title":"Gluco-metabolic effects of oral and intravenous alcohol administration in men","volume":"8","author":"Lanng","year":"2019","journal-title":"Endocr. Connect"},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00006676-199801000-00011","article-title":"The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium antagonism with nifedipine: no evidence for a role of glucagon-like peptide-1 (GLP-1)","volume":"16","author":"Svartberg","year":"1998","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13211","article-title":"The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib52","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J. Stud. Alcohol Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib54","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"22","key":"10.1016\/j.phrs.2024.107312_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharm. Toxicol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib57","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2024.107312_bib58","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.phrs.2024.107312_bib59","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib60","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib62","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib63","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/npp.2015.47","article-title":"Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior","volume":"40","author":"Harasta","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib65","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol. Behav."},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib67","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2024.107312_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder","volume":"99","author":"Chaves Filho","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2024.107312_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2021.711750","article-title":"Glucagon-like peptide-1 agonist exendin-4 facilitates the extinction of cocaine-induced condition place preference","volume":"15","author":"Zhu","year":"2021","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.phrs.2024.107312_bib71","article-title":"Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.phrs.2024.107312_bib72","article-title":"Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.phrs.2024.107312_bib73","article-title":"Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice","volume":"15","author":"Zhu","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.phrs.2024.107312_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2018.11.001","article-title":"Cocaine and cocaine expectancy increase growth hormone, ghrelin, GLP-1, IGF-1, adiponectin, and corticosterone while decreasing leptin, insulin, GIP, and prolactin","volume":"176","author":"You","year":"2019","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.phrs.2024.107312_bib75","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","author":"Merkel","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.phrs.2024.107312_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107312_bib77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.drugalcdep.2017.07.033","article-title":"Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses","volume":"180","author":"Bouhlal","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib80","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib81","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.phrs.2024.107312_bib82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2024.107312_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2024.107312_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2024.107312_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104616","article-title":"The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats","volume":"133","author":"\u0141upina","year":"2020","journal-title":"Neurochem Int."},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27082478","article-title":"Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal","volume":"27","author":"Listos","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.phrs.2024.107312_bib87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2024.107312_bib88","author":"Appenzeller","year":"2024","journal-title":"Obes. Drug cuts opiate craving"},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib89","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib90","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib92","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.phrs.2024.107312_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2024.107312_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41398-020-0756-3","article-title":"Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study","volume":"10","author":"Farokhnia","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2024.107312_bib97","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/17425255.2018.1441286","article-title":"Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?","volume":"14","author":"Doggrell","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2024.107312_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2024.107312_bib99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jdi.12463","article-title":"Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin\/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus","volume":"7 Suppl 1","author":"Knudsen","year":"2016","journal-title":"J. Diabetes Invest."},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03033808","article-title":"Dopamine and reward: the anhedonia hypothesis 30 years on","volume":"14","author":"Wise","year":"2008","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib101","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2024.107312_bib102","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2023_424","article-title":"Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit\/stress surfeit disorder","author":"Koob","year":"2023","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"8","key":"10.1016\/j.phrs.2024.107312_bib103","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2024.107312_bib104","series-title":"Alcohol and Alcohol-related Diseases","first-page":"687","article-title":"Alcohol Use Disorder: Stress, Negative Reinforcement, and Negative Urgency","author":"Vendruscolo","year":"2023"},{"key":"10.1016\/j.phrs.2024.107312_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"issue":"14","key":"10.1016\/j.phrs.2024.107312_bib106","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020734","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","volume":"10","author":"Li","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2024.107312_bib107","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib108","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int. J. Obes."},{"issue":"7","key":"10.1016\/j.phrs.2024.107312_bib109","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2337\/dc18-2584","article-title":"Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies","volume":"42","author":"Zhang","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2024.107312_bib110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.phrs.2024.107312_bib111","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2024.107312_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102343","article-title":"Type 2 diabetes mellitus\/obesity drugs: a neurodegenerative disorders savior or a bridge too far?","volume":"98","author":"Kopp","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib113","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib114","first-page":"1010","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes\u00a0Obes. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2024.107312_bib115","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"issue":"23","key":"10.1016\/j.phrs.2024.107312_bib116","doi-asserted-by":"crossref","first-page":"10470","DOI":"10.1523\/JNEUROSCI.22-23-10470.2002","article-title":"The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness","volume":"22","author":"Kinzig","year":"2002","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107312_bib117","doi-asserted-by":"crossref","first-page":"R726","DOI":"10.1152\/ajpregu.1997.272.2.R726","article-title":"Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats","volume":"272","author":"Thiele","year":"1997","journal-title":"Am. J. Physiol. Regul.\u00a0Integr. Comp. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107312_bib118","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1523\/JNEUROSCI.20-04-01616.2000","article-title":"The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride","volume":"20","author":"Seeley","year":"2000","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.phrs.2024.107312_bib119","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: why it still matters, and the need for consilience","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"5335","key":"10.1016\/j.phrs.2024.107312_bib120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.278.5335.45","article-title":"Addiction is a brain disease, and it matters","volume":"278","author":"Leshner","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib121","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2024.107312_bib122","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diab.45.6.832","article-title":"Glucagon-like peptide i receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I","volume":"45","author":"\u00d8rskov","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2024.107312_bib123","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.phrs.2024.107312_bib124","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","author":"Rhea","year":"2023","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.phrs.2024.107312_bib125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T18:53:58Z","timestamp":1728413638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824002573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":125,"alternative-id":["S1043661824002573"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107312","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review \u2013\u00a0Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107312"}}